Research Funding extended for E112K as a Novel Therapy for IBD

The Broad Medical Research Program at the Crohn’s & Colitis Foundation of America has extended their Inflammatory Bowel Disease Grant to Norton Lab for a second year. The project, entitled E112K as a Novel Therapy for Irritable Bowel Disease (IBD), was inspired by Dr. Norton observing in the course of her adjuvant research the novel anti-inflammatory properties in a mutated bacterially-derived protein called E112K. The objective of this research is to determine if E112K will be beneficial in mouse models of  IBD, as a new therapy or prophylaxes.

We believe that the unique anti-inflammatory and immunosuppressive properties of E112K make it an excellent candidate therapy for IBD and, potentially, a means of identifying novel mechanisms for the treatment of IBD. We hypothesize that E112K therapy will ameliorate IBD colitis by preventing inflammatory responses in resident immune cells and epithelial cells within the gut mucosa. The basis for our hypothesis lies in the unique properties of E112K that we have discovered by examining the class of molecules from which E112K belongs, i.e., non-toxic derivatives of heat-labile enterotoxin from E. coli (LT).

Comments are closed.